LDS1 Antibody

What exactly is LSD1 and why is it important in epigenetic research?

LSD1 (Lysine-specific demethylase 1, also designated KDM1A) is a nuclear protein that functions as a histone demethylase, specifically targeting the demethylation of Histone H3K4me1 and Histone H3K4me2, which are methylation sites associated with transcriptional activation . LSD1 can also demethylate Histone H3K9me1 and Histone H3K9me2, modifications often associated with transcriptional repression .

Beyond histones, LSD1 is able to demethylate Lys370me1 and Lys370me2 in the regulatory domain of the tumor suppressor p53 . LSD1 is a flavin-dependent amine oxidase that acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed .

LSD1 was identified as a subunit of various protein complexes including CTBP, CoREST, NuRD, and BRAF35, making it a critical component of several chromatin remodeling mechanisms .

Which applications are LSD1 antibodies commonly used for in research?

Based on the collected research data, LSD1 antibodies are commonly used in:

LSD1 antibodies are particularly valuable in epigenetic research for analyzing gene expression regulation and chromatin modifications across different cellular contexts .

How should I validate the specificity of an LSD1 antibody?

Validation of LSD1 antibodies should follow multiple complementary approaches:

• Knockout/knockdown validation: Comparing staining patterns between wild-type cells and those with LSD1 knockdown or knockout. Several antibodies in the search results (e.g., , ) show validation using this method with Western blot comparing control and LSD1 siRNA-treated cells.

• Western blot band verification: Confirming a single band at the expected molecular weight (approximately 110 kDa for LSD1) .

• Positive control samples: Using cell lines with known LSD1 expression levels. For example, HeLa nuclear extract (Catalog No. 36010) is recommended as a positive control for certain LSD1 antibodies .

• Immunoprecipitation validation: Verifying that the antibody can successfully pull down LSD1 protein complexes from cell lysates .

• Cross-reactivity testing: Ensuring the antibody is specific across multiple species if cross-reactivity is claimed. Several antibodies have validated reactivity with human, mouse, and in some cases rat and monkey samples .

• Phospho-specific validation: For phospho-specific antibodies like Phospho-LSD1 (Ser131), validation should include treatment with relevant kinase inhibitors or phosphatase .

How should I optimize ChIP protocols specifically for LSD1 antibodies?

For optimal ChIP results with LSD1 antibodies, researchers should consider the following protocol optimizations:

• Antibody-to-chromatin ratio: Use approximately 10 μl of antibody and 10 μg of chromatin (approximately 4 × 10^6 cells) per IP for optimal results .

• Enzymatic vs. sonication fragmentation: LSD1 antibodies have been validated with enzymatic chromatin IP kits like SimpleChIP® Enzymatic Chromatin IP Kits , but both methods can work depending on your experimental setup.

• Appropriate controls: Include:

  • Input chromatin (pre-immunoprecipitation sample)

  • IgG negative control (matching the host species of your LSD1 antibody)

  • Positive control antibody targeting a known abundant mark (e.g., H3K4me3)

• Cross-linking optimization: Standard 1% formaldehyde for 10 minutes at room temperature works well for most histone demethylases including LSD1.

• Washing stringency: Optimize salt concentration in wash buffers to maintain specificity while minimizing background.

• Validation of ChIP-grade antibodies: Specifically use antibodies validated for ChIP applications, as not all LSD1 antibodies perform equally in this technique .

• Sonication verification: Ensure chromatin is properly fragmented to 200-500 bp before immunoprecipitation.

When analyzing LSD1 binding by ChIP-seq, researchers should look for enrichment at both active and repressed genes, as LSD1 can function as both a repressor and activator depending on the genomic context .

How can I distinguish between LSD1's demethylase-dependent and demethylase-independent functions in my experiments?

Distinguishing between LSD1's demethylase-dependent and demethylase-independent functions requires careful experimental design:

• Pharmacological approach:

  • Use specific LSD1 inhibitors that target different mechanisms:

  • GSK-LSD1 acts primarily on the demethylase activity

  • SP-2509 acts as an allosteric inhibitor that blocks demethylase-independent functions

  • Compare effects between these inhibitor types to differentiate mechanisms

• Mutational approach:

  • Use LSD1 constructs with point mutations in the catalytic domain that abolish enzymatic activity but maintain protein-protein interactions

  • Compare with wild-type LSD1 to determine which functions are preserved in the enzymatically inactive mutant

• Readouts to assess:

  • Histone methylation status (H3K4me1/2 and H3K9me1/2) to confirm demethylase function

  • Protein-protein interactions using co-immunoprecipitation or proximity ligation assays to assess scaffold functions

  • Gene expression profiles to identify demethylase-independent target genes

Research has revealed that LSD1 can function independently of its demethylase activity in certain contexts. For example, in prostate cancer, LSD1 promotes survival independently of its demethylase function and of the androgen receptor by activating a lethal gene network in collaboration with its binding protein ZNF217 .

What experimental design strategies should I use to study LSD1's role in stem cell properties of cancer?

To investigate LSD1's role in cancer stem cell (CSC) properties, researchers should consider the following experimental design approaches:

• In vitro stemness assays:

  • Sphere formation assays to assess self-renewal capacity

  • Colony formation assays to evaluate clonogenic potential

  • Expression analysis of stemness markers (e.g., SOX2, OCT4, NANOG)

  • Serial dilution transplantation assays to quantify CSC frequency

• LSD1 manipulation strategies:

  • Genetic approaches: CRISPR/Cas9 knockout, shRNA knockdown, or overexpression of LSD1

  • Pharmacological approaches: Treatment with LSD1 inhibitors like GSK-LSD1 or SP-2509

  • Compare effects between LSD1 inhibition and LSD1 protein depletion

• Combined treatment designs:

  • As shown in head and neck squamous cell carcinoma (HNSCC) research, combining LSD1 inhibition with immune checkpoint inhibitors (anti-PD-1) can overcome tumor immune evasion and greatly inhibit tumor growth

  • Design factorial experiments testing LSD1 inhibitors with standard of care therapies

• Model systems:

  • Patient-derived xenografts to maintain tumor heterogeneity

  • Both immune-deficient and immune-competent models to capture complete biological effects

  • 3D organoid cultures to better recapitulate tumor architecture

• Readouts and endpoints:

  • Changes in CSC marker expression (e.g., Bmi-1)

  • Tumorigenicity in limiting dilution assays

  • Resistance to conventional therapies

  • Metastatic potential

  • Immune infiltration (particularly CD8+ T cells)

What are the optimal conditions for Western blotting with LSD1 antibodies?

Based on the search results, here are the optimal conditions for Western blotting with LSD1 antibodies:

• Sample preparation:

  • Nuclear extracts are preferred as LSD1 is a nuclear protein

  • 20-40 μg of protein is typically sufficient for detection

  • Both whole cell lysates and nuclear extracts have been successfully used

• Recommended dilutions:

  • Most LSD1 antibodies work well at dilutions between 1:500-1:2000

  • For phospho-specific LSD1 antibodies, 1:1000 is commonly recommended

• Expected molecular weight:

  • LSD1 typically appears at approximately 110 kDa

  • Note that the theoretical MW is around 93 kDa, but the observed MW is often higher due to post-translational modifications

• Blocking conditions:

  • 5% skimmed milk in TBS-Tween has been verified to work well

  • For phospho-specific antibodies, BSA may be preferable to milk

• Verification methods:

  • Include positive controls (e.g., HeLa nuclear extracts)

  • For validation, include samples with LSD1 knockdown (siRNA) as negative controls

• Detection systems:

  • Both chemiluminescence and fluorescence-based detection systems work well

  • For quantitative analysis, fluorescence-based systems may offer superior linearity

• Alternative approaches:

  • Simple Western automated capillary-based systems have been validated for certain LSD1 antibodies at 1:500 dilution

How should I design experiments to investigate LSD1's role in drug resistance mechanisms?

To investigate LSD1's role in drug resistance mechanisms, consider the following experimental design approach:

• Model selection:

  • Use paired sensitive/resistant cell line models

  • Develop resistance models through long-term exposure to relevant therapeutics

  • Include patient-derived samples from treatment-naive and post-treatment relapse patients

• LSD1 manipulation strategies:

  • Pharmacological inhibition: Test both catalytic (GSK-LSD1) and allosteric (SP-2509) inhibitors

  • Genetic approaches: CRISPR/Cas9 knockout, shRNA knockdown, or overexpression of LSD1

  • Time-course experiments: Acute vs. chronic LSD1 inhibition

• Combination treatment designs:

  • Factorial design testing LSD1 inhibitors with standard therapeutic agents

  • Sequential vs. simultaneous treatment protocols

  • Dose-response matrices to identify synergistic combinations

• Molecular analysis:

  • ChIP-seq to map LSD1 binding sites in sensitive vs. resistant states

  • RNA-seq to identify LSD1-dependent transcriptional changes

  • Proteomics to assess changes in signaling pathways

  • Co-immunoprecipitation to identify context-specific LSD1 protein complexes

• Functional assays:

  • Cell viability/proliferation assays

  • Apoptosis assays

  • Invasion/migration assays

  • Cancer stem cell assays (sphere formation, limiting dilution)

• In vivo validation:

  • Use xenograft models with acquired resistance

  • Test combinations in appropriate immune-competent models

  • Analyze tumor samples for LSD1 activity, target engagement, and pharmacodynamic markers

Research has shown that LSD1 can promote resistance to conventional therapies by maintaining cancer stem cell properties in various tumor types including HNSCC and prostate cancer . Targeting LSD1 has shown promise in overcoming resistance mechanisms, particularly when combined with other therapeutic approaches.

What controls should I include when studying LSD1 phosphorylation?

When studying LSD1 phosphorylation, particularly at sites like Ser131, include these essential controls:

• Validation controls:

  • Phosphatase treatment: Samples treated with lambda phosphatase should show decreased or absent signal with phospho-specific antibodies

  • Kinase inhibition: Treatment with CK2 inhibitors should reduce phosphorylation at Ser131, Ser137, and Ser166 sites

  • Total LSD1 detection: Always probe for total LSD1 in parallel to normalize phospho-signal

• Experimental controls:

  • Positive controls: Use cell types or conditions known to induce LSD1 phosphorylation (e.g., DNA damage for Ser131/Ser137)

  • Negative controls: Include LSD1 knockout/knockdown samples to confirm antibody specificity

  • Biological variability: Use multiple biological replicates to account for variation

• Technical validation:

  • Peptide competition assays: Pre-incubation with phosphorylated peptide should block antibody binding

  • Phosphomimetic and phospho-dead mutants: Compare S131E (mimetic) and S131A (dead) LSD1 constructs

  • Antibody cross-reactivity: Test against related proteins with similar phosphorylation motifs

• Contextual controls:

  • Time-course analysis: Monitor phosphorylation dynamics following stimulation

  • Dose-response: Vary the intensity of stimulation to assess proportional changes

  • Subcellular fractionation: Determine if phosphorylation affects LSD1 localization

Research has shown that LSD1 is phosphorylated by CK2 at Ser131, Ser137, and Ser166 . Phosphorylation at Ser131 and Ser137 has been shown to facilitate RNF168-dependent recruitment to sites of DNA damage, representing a non-canonical function of LSD1 .

How can I optimize immunofluorescence protocols for LSD1 antibodies?

For optimal immunofluorescence results with LSD1 antibodies, consider these protocol recommendations:

• Fixation and permeabilization:

  • 4% paraformaldehyde for 5 minutes has been validated for LSD1 staining in K-562 cells

  • Alternative fixation: Methanol fixation (-20°C, 10 minutes) can improve nuclear antigen accessibility

  • Permeabilization: 0.1-0.5% Triton X-100 in PBS for 10 minutes

• Blocking and antibody incubation:

  • Block with 5% normal serum (matching secondary antibody host) in PBS with 0.1% Triton X-100

  • Recommended dilutions range from 1:200-1:500 for most LSD1 antibodies

  • Incubate primary antibody overnight at 4°C for optimal signal-to-noise ratio

• Controls and validation:

  • Include LSD1 knockdown/knockout cells as negative controls

  • Co-stain with established nuclear markers to confirm localization

  • Perform peptide competition assays to verify specificity

• Expected staining pattern:

  • LSD1 should show predominantly nuclear localization

  • Look for homogeneous nuclear staining with possible exclusion from nucleoli

  • Co-localization with chromatin is expected

• Troubleshooting weak signal:

  • Extend primary antibody incubation time

  • Optimize antigen retrieval methods for fixed tissue sections

  • Try tyramide signal amplification for low abundance detection

• Multi-color immunofluorescence considerations:

  • When designing multicolor panels, consider fluorochrome selection based on antigen abundance

  • For 3-4 color experiments, choose fluorochromes requiring minimal compensation (FITC, APC, Pacific Blue)

  • For 5-8 color experiments, include PE, PE-Cy5, PE-Cy5.5, PE-Cy7, and APC-Cy7

Research shows that LSD1 co-localizes with normal and polyQ-expanded AR in multiple cell types, including MN1 cells, patient-derived iPSCs differentiated to motor neurons, and in spinal cord tissues .

How can I resolve inconsistent results between different LSD1 antibodies?

When facing inconsistent results between different LSD1 antibodies, implement the following troubleshooting strategy:

• Epitope mapping and antibody selection:

  • Compare the epitope regions targeted by each antibody:

    • N-terminal antibodies (aa 1-100)

    • C-terminal antibodies

    • Full-length recombinant protein-derived antibodies

  • Different epitopes may be differentially accessible in various experimental conditions

• Isoform consideration:

  • LSD1 has multiple isoforms (LSD1-2a, LSD-8a, and LSD1-2a/8a)

  • Ensure your antibodies can detect all relevant isoforms for your research question

  • Review antibody documentation to determine which isoforms are recognized

• Post-translational modifications:

  • Phosphorylation (e.g., at Ser131, Ser137, Ser166) can affect antibody binding

  • Other PTMs may mask epitopes in certain contexts

• Cross-validation strategies:

  • Use multiple antibodies targeting different epitopes

  • Verify results with orthogonal techniques (e.g., mass spectrometry)

  • Include genetic controls (knockdown/knockout) for each antibody

• Application-specific optimization:

  • Different antibodies may perform better in specific applications

  • Systematically test each antibody across multiple techniques

  • Compare antibody performance across different buffer conditions and protocols

• Antibody validation hierarchy:

  • Prioritize knockout-validated antibodies

  • Consider monoclonal antibodies for higher consistency

  • Evaluate lot-to-lot variability by requesting technical support data

Research shows that the observed molecular weight of LSD1 can vary from the predicted 93 kDa due to post-translational modifications, which may affect antibody binding and contribute to inconsistent results .

What experimental approaches should I use to study LSD1's context-dependent functions in different tissues?

To study LSD1's context-dependent functions across different tissues, implement these experimental approaches:

• Tissue-specific conditional knockout models:

  • Use Cre-loxP systems targeting specific tissues (e.g., intestinal epithelium-specific LSD1 knockout)

  • Implement inducible systems to study both developmental and adult roles

  • Compare phenotypes across different tissue-specific knockouts

• Single-cell analysis approaches:

  • Single-cell RNA-seq to identify cell type-specific LSD1-dependent transcriptional programs

  • scATAC-seq to assess chromatin accessibility changes

  • CUT&RUN or CUT&Tag profiling for cell type-specific binding patterns

• Organoid and primary culture systems:

  • Establish tissue-specific organoid cultures (e.g., intestinal organoids) to study LSD1 in controlled environments

  • Compare effects of LSD1 inhibition across organoids derived from different tissues

  • Use human organoids to validate findings from animal models

• Time-course experiments:

  • Study LSD1 functions during:

    • Development and postnatal maturation

    • Homeostasis maintenance

    • Tissue regeneration after injury

    • Disease progression

• Context-dependent protein interactions:

  • Perform tissue-specific immunoprecipitation-mass spectrometry to identify tissue-specific interactors

  • Use proximity labeling approaches (BioID, APEX) to capture transient interactions

  • Compare LSD1 complexes across different cellular states

Research has demonstrated clear tissue-specific roles for LSD1. For example, in intestinal epithelium, LSD1 represses a neonatal/reparative gene program and controls maturation . During postnatal development, intestinal-epithelial intrinsic expression of LSD1 is necessary for epithelial maturation and maintenance of this developed state during adulthood . LSD1 inhibition in this context enhances tissue repair after radiation injury .

In contrast, in cancer contexts like prostate cancer, LSD1 activates a lethal gene network and promotes survival independently of its demethylase function , showing how its functions can vary dramatically between contexts.

How can I design experiments to evaluate LSD1 inhibitors for cancer therapy?

When designing experiments to evaluate LSD1 inhibitors for cancer therapy, implement the following comprehensive approach:

• Inhibitor selection and characterization:

  • Compare different inhibitor classes:

    • Catalytic inhibitors (e.g., GSK-LSD1) that target demethylase activity

    • Allosteric inhibitors (e.g., SP-2509) that block protein-protein interactions

    • Novel compounds with unique mechanisms

  • Validate target engagement using:

    • Histone methylation status (H3K4me1/2, H3K9me1/2)

    • Thermal shift assays

    • Cellular thermal shift assays (CETSA)

• In vitro assessment:

  • Dose-response curves across diverse cancer cell lines

  • Time-course experiments to distinguish cytostatic vs. cytotoxic effects

  • Combine with standard-of-care therapies to assess synergy

  • Evaluate effects on cancer stem cell populations

• Mechanism of action studies:

  • RNA-seq to identify transcriptional changes

  • ChIP-seq to map changes in histone modification patterns

  • Proteomics to assess signaling pathway alterations

  • Metabolomics to identify metabolic dependencies

• In vivo evaluation:

  • Use both xenograft and syngeneic tumor models

  • For certain cancers (e.g., HNSCC), combine with immune checkpoint inhibitors

  • Assess pharmacokinetics, bioavailability, and tumor penetration

  • Monitor appropriate biomarkers (e.g., histone methylation in tumor biopsies)

• Patient-derived models:

  • Test efficacy in patient-derived xenografts

  • Use organoid drug screening platforms

  • Correlate response with molecular features (LSD1 expression levels, mutation status)

Research has shown that LSD1 inhibitors can effectively target cancer stem cells in HNSCC , suppress castration-resistant prostate cancer via non-canonical mechanisms , and may have therapeutic potential in various other malignancies through both demethylase-dependent and independent functions.

What approaches should I use to investigate LSD1's role in metabolic disorders?

To investigate LSD1's role in metabolic disorders, implement these comprehensive experimental approaches:

• Metabolic phenotyping:

  • Compare effects of LSD1 inhibition between lean and obese states

  • Measure key metabolic parameters:

    • Food intake and body weight

    • Glucose tolerance and insulin sensitivity

    • Lipid profiles and adipose tissue inflammation

    • Energy expenditure and respiratory exchange ratio

• Tissue-specific analyses:

  • Focus on insulin-responsive tissues:

    • Liver: Assess hepatic steatosis, gluconeogenesis, lipogenesis

    • Adipose tissue: Examine inflammation, lipolysis rates, adipokine secretion

    • Muscle: Measure glucose uptake, glycogen synthesis, mitochondrial function

    • Pancreas: Evaluate β-cell function and insulin secretion

• Intervention studies:

  • Acute vs. chronic LSD1 inhibition

  • Prevention vs. reversal paradigms

  • Dietary challenges (Western diet, high-fat diet)

  • Exercise intervention combined with LSD1 modulation

• Molecular mechanisms:

  • Determine tissue-specific LSD1 targets using ChIP-seq

  • Identify context-dependent protein complexes by co-immunoprecipitation

  • Map metabolic pathway alterations using transcriptomics and proteomics

  • Study post-translational modifications of metabolic enzymes

• Translation to human studies:

  • Analyze LSD1 expression in human metabolic tissue biopsies

  • Correlate with clinical parameters and disease severity

  • Test LSD1 inhibitors on human organoids or explant cultures

Research has shown that systemic LSD1 inhibition with GSK-LSD1 reduces food intake and body weight, ameliorates nonalcoholic fatty liver disease (NAFLD), and improves insulin sensitivity and glycemic control in mouse models of obesity, while having minimal effects on lean mice . This suggests LSD1 has a context-dependent role in promoting maladaptive changes specifically in the obese state.

White adipose tissue has been identified as the major site of insulin sensitization by GSK-LSD1, where it reduces adipocyte inflammation and lipolysis .

How can I use LSD1 antibodies to study its role in neurodegenerative diseases?

To investigate LSD1's role in neurodegenerative diseases using LSD1 antibodies, implement these specialized experimental approaches:

• Tissue and cell type-specific analysis:

  • Compare LSD1 expression and localization across:

    • Patient brain tissue sections vs. age-matched controls

    • Different neural cell types (neurons, astrocytes, microglia)

    • Disease-relevant regions vs. unaffected areas

  • Use multiplexed immunofluorescence with cell type-specific markers

• Post-translational modification assessment:

  • Investigate disease-specific alterations in LSD1 phosphorylation

  • Study LSD1's involvement in DNA damage response through phospho-specific antibodies (Ser131, Ser137)

  • Examine other modifications that may affect LSD1 function in neurodegeneration

• Protein-protein interaction studies:

  • Use co-immunoprecipitation to identify disease-specific LSD1 complexes

  • Apply proximity ligation assays to visualize interactions in situ

  • Study LSD1's interaction with disease-relevant proteins (e.g., polyQ-expanded proteins)

• Model systems:

  • Patient-derived iPSC neurons

  • Transgenic animal models of neurodegeneration

  • Brain organoids modeling disease progression

• Therapeutic targeting:

  • LSD1/PRMT6-targeting gene therapy approaches for diseases like spinobulbar muscular atrophy

  • Combination with other epigenetic modulators

  • Test catalytic vs. scaffold function inhibitors

Research has shown that LSD1 forms a complex with polyQ-expanded androgen receptor (AR) in spinobulbar muscular atrophy (SBMA) . LSD1 acts as a co-activator of polyQ-expanded AR, suggesting its involvement in disease pathogenesis. Targeting LSD1 in combination with other approaches (e.g., PD-1 blockade) has shown therapeutic potential in preclinical models of neurodegeneration .